Sanofi-aventis

Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt.

Euroapi Hungary Limited Liability Company

Nicox S.a.

Andrea Sántáné Csutor

Lajos T Nagy

Gabor Kovacs

Sandor Virag

Nicoletta Almirante

Csaba Gönczi

Györgyné Szvoboda

Tiborné Szomor

Gergely Héja

István Hermecz

Dezso Korbonits

Pal Kiss

Irén Hortobágyi

Zsuzsanna Kardos

Laszlo Tardos

István Lászlófi

Katalin Marmarosi Nee Kellner

Imre Bata

Gyula Papp

Vera Gergely

Peter S Kormoczy

Laszlo Szekeres

László Takács

Attila Simon

Zoltan Vargai

Eva Udvari

Ildikó Meleg

Judit Póti

Mariusz Kertész

Ágota Smelkóné Esek

Kálmán Simon

Árpád Illár

Éva Csikós

Csilla Majláth

Gergelyné Héja

Felix Hajdú

Eva Csikós

Szabolcs Kovács

Gael Ronsin

The present invention relates to a process for the preparation of a chiral prostaglandin enol intermediate of formula 1, comprising the steps of: separating a compound of formula 16-(R,S)-10 into its diastereomers by fractional crystallisation, reducing the 15-oxo group of the compound of formula 16-(R)-10, thereby obtaining a compound of formula 15-(R,S), 16-(R)-11, followed by removing the protecting group of the compound of formula 15-(R,S), 16-(R)-11, and isolating the compound of formula 1, and optionally, crystallizing the compound of formula 1. Optionally, the undesired isomer formed during fractional crystallization can be epimerized and further amount of the desired isomer can be recovered from the resulting mixture. The present invention also provides novel intermediates useful in the process. The invention further relates to a process for fractional crystallization of the compound of formula 16-(R,S)-10.

Process for the preparation of a chiral prostaglandin enol intermediate and intermediate compounds useful in the process

The invention relates to a process for the preparation of a compound of the formula (I) by reacting a compound of the formula (II) with a compound of the formula (III) characterized by dissolving the compounds of the formula (II) and formula (III) in a water-inmiscible organic solvent in the presence of a phase transfer catalyst, reacting with a.) an aqeuos solution of a base, or b.) a base in solid form directly and if desired transforming the compound of formula (I) thus obtained into its salt. 

Process for the preparation of 3-spiro'cyclohexan-1,3&#x2032;-&#x2032;3H!indolin-2&#x2032;-one! derivatives

The invention relates to a process for the preparation of spiro[(4-cyclohexanone)-[3H]indol]-2'[1&#x2032;H]-one derivatives of the general formula Iwherein Rand Rindependently stand for hydrogen, Calkyl, Calkoxy, Calkylthio, Cpolyfluoroalkyl, Cpolyfluoroalkoxy, Ccycloalkyloxy, Ccycloalkylthio, phenoxy, benzyloxy or nitro group&#x2014;,characterized by reacting an indolin-2-one derivative of the general formula IIwherein Rand Rare as defined above&#x2014;with a compound capable for introducing a protective group, selected from 2-tetrahydropyranyl, 1-diethoxy-methylene or Calkoxycarbonylethyl group, coupling the compound of general formula III,thus obtained&#x2014;wherein Rand Rare as defined above and A stands for a protective group, selected from 2-tetrahydropyranyl, 1-diethoxy-methylene or Calkoxycarbonylethyl group&#x2014;with an acrylic acid Cester, cyclizing the resulting compound of the general formula IVwherein R, Rand A are as defined above, Rstands for Calkyl group&#x2014;, eliminating the &#x2014;COORgroup and the A protective group of the keto-ester of general formula Vwherein R, R, Rand A are as defined above, optionally without isolation of the compounds of the general formulae IV

Process for the preparation of spiro[(4-cyclohexanone)-[3]indol]-2'[1&#x2032;H]-one derivatives

The invention relates to novel diphenylpropylamine derivatives of the general formula (I). ##STR1## R.sup.1 stands for hydrogen or a methyl group; R.sup.2 stands for hydrogen, a methyl or n-decyl group;

Diphenkylpropylamines for the therapy of heart disease

Growing community of inventors

Budapest, Hungary

Andrea Sántáné Csutor